Colleen Moriarty

Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) will soon offer a new cellular therapy for patients living with melanoma that has spread to other parts of the body. Tumor-infiltrating lymphocyte therapy (TIL), or lifileucel, was recently approved by the U.S. Food and Drug Administration. SCH is the first and only hospital in Connecticut to offer the therapy. TIL therapy uses a patient’s immune cells collected at the hospital from their tumor. Then, the cells are sent to a laboratory…